Theresa W Kim1, Alexander Y Walley2, Timothy C Heeren3, Gregory J Patts4, Alicia S Ventura5, Gabriel B Lerner6, Nicholas Mauricio7, Richard Saitz8. 1. Clinical Addiction Research and Education (CARE) Unit (TWK, AYW, ASV, RS), Section of General Internal Medicine, Boston University School of Medicine (GBL, NM), Boston Medical Center, Boston, MA, United States. Electronic address: theresa.kim@bmc.org. 2. Clinical Addiction Research and Education (CARE) Unit (TWK, AYW, ASV, RS), Section of General Internal Medicine, Boston University School of Medicine (GBL, NM), Boston Medical Center, Boston, MA, United States. Electronic address: alexander.walley@bmc.org. 3. Department of Biostatistics (TH), Data Coordinating Center (GJP), Department of Community Health Sciences (RS), Boston University School Public Health, Boston, MA, United States. Electronic address: tch@bu.edu. 4. Department of Biostatistics (TH), Data Coordinating Center (GJP), Department of Community Health Sciences (RS), Boston University School Public Health, Boston, MA, United States. Electronic address: gpatts@bu.edu. 5. Department of Biostatistics (TH), Data Coordinating Center (GJP), Department of Community Health Sciences (RS), Boston University School Public Health, Boston, MA, United States. Electronic address: Alicia.ventura@bmc.org. 6. Clinical Addiction Research and Education (CARE) Unit (TWK, AYW, ASV, RS), Section of General Internal Medicine, Boston University School of Medicine (GBL, NM), Boston Medical Center, Boston, MA, United States. Electronic address: gblerner@bu.edu. 7. Clinical Addiction Research and Education (CARE) Unit (TWK, AYW, ASV, RS), Section of General Internal Medicine, Boston University School of Medicine (GBL, NM), Boston Medical Center, Boston, MA, United States. Electronic address: nmaur@bu.edu. 8. Clinical Addiction Research and Education (CARE) Unit (TWK, AYW, ASV, RS), Section of General Internal Medicine, Boston University School of Medicine (GBL, NM), Boston Medical Center, Boston, MA, United States; Department of Biostatistics (TH), Data Coordinating Center (GJP), Department of Community Health Sciences (RS), Boston University School Public Health, Boston, MA, United States. Electronic address: rsaitz@bu.edu.
Abstract
INTRODUCTION: People living with HIV (PLWH) are at risk of both polypharmacy and unintentional overdose yet there are few data on whether polypharmacy increases risk of overdose. The study objective was to determine if the number and type of medication (e.g., sedating) were associated with non-fatal overdose (OD) among PLWH with past-year substance dependence or a lifetime history of injection drug use. MATERIALS AND METHODS: This was a longitudinal study of adults recruited from two urban, safety-net HIV clinics. Outcomes were i) lifetime and ii) past-year non-fatal OD assessed at baseline and a 12-month follow-up. We used logistic regression to examine the association between each outcome and the number of medications (identified from the electronic medical record) in the following categories: i) overall medications, ii) non-antiretroviral (non-ARV), iii) sedating, iv) non-sedating, as well as any vs no opioid medication and any vs no non-opioid sedating medication. Covariates included demographics, medical comorbidities, depressive and anxiety symptoms, and substance use. RESULTS: Among 250 participants, 80% were prescribed a sedating medication, 50% were prescribed an opioid; 51% exceeded risky drinking limits. In the past month, 23% reported illicit opioid use and 9% illicit opioid sedative use; 37% reported lifetime non-fatal OD and 7% past-year non-fatal OD. The median number (interquartile range) of total medications was 10 (7, 14) and 2 (1, 3) sedating. The odds of lifetime non-fatal OD were significantly higher with each additional sedating medication (OR 1.26, 95% CI 1.08, 1.46) and any opioid medication (OR 2.31; 95% CI 1.37, 3.90), but not with each overall, non-ARV, or non-sedating medication. The odds of past year non-fatal OD were greater with each additional sedating medication (OR 1.18; 95% CI 1.00, 1.39, p=0.049), each additional non-ARV medication (OR 1.07; 95% CI 1.00, 1.15, p=0.048), and non-significantly for any opioid medication (OR 2.23; 95% CI 0.93, 5.35). CONCLUSIONS: In this sample of PLWH with substance dependence and/or injection drug use, number of sedating medications and any opioid were associated with non-fatal overdose; sedating medications were prescribed to the majority of patients. Polypharmacy among PLWH and substance dependence warrants further research to determine whether reducing sedating medications, including opioids, lowers overdose risk.
INTRODUCTION:People living with HIV (PLWH) are at risk of both polypharmacy and unintentional overdose yet there are few data on whether polypharmacy increases risk of overdose. The study objective was to determine if the number and type of medication (e.g., sedating) were associated with non-fatal overdose (OD) among PLWH with past-year substance dependence or a lifetime history of injection drug use. MATERIALS AND METHODS: This was a longitudinal study of adults recruited from two urban, safety-net HIV clinics. Outcomes were i) lifetime and ii) past-year non-fatal OD assessed at baseline and a 12-month follow-up. We used logistic regression to examine the association between each outcome and the number of medications (identified from the electronic medical record) in the following categories: i) overall medications, ii) non-antiretroviral (non-ARV), iii) sedating, iv) non-sedating, as well as any vs no opioid medication and any vs no non-opioid sedating medication. Covariates included demographics, medical comorbidities, depressive and anxiety symptoms, and substance use. RESULTS: Among 250 participants, 80% were prescribed a sedating medication, 50% were prescribed an opioid; 51% exceeded risky drinking limits. In the past month, 23% reported illicit opioid use and 9% illicit opioid sedative use; 37% reported lifetime non-fatal OD and 7% past-year non-fatal OD. The median number (interquartile range) of total medications was 10 (7, 14) and 2 (1, 3) sedating. The odds of lifetime non-fatal OD were significantly higher with each additional sedating medication (OR 1.26, 95% CI 1.08, 1.46) and any opioid medication (OR 2.31; 95% CI 1.37, 3.90), but not with each overall, non-ARV, or non-sedating medication. The odds of past year non-fatal OD were greater with each additional sedating medication (OR 1.18; 95% CI 1.00, 1.39, p=0.049), each additional non-ARV medication (OR 1.07; 95% CI 1.00, 1.15, p=0.048), and non-significantly for any opioid medication (OR 2.23; 95% CI 0.93, 5.35). CONCLUSIONS: In this sample of PLWH with substance dependence and/or injection drug use, number of sedating medications and any opioid were associated with non-fatal overdose; sedating medications were prescribed to the majority of patients. Polypharmacy among PLWH and substance dependence warrants further research to determine whether reducing sedating medications, including opioids, lowers overdose risk.
Authors: Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: Maria Rosa Cantudo-Cuenca; Rocio Jiménez-Galán; Carmen V Almeida-Gonzalez; Ramón Morillo-Verdugo Journal: J Manag Care Spec Pharm Date: 2014-08
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Bradley M Mathers; Louisa Degenhardt; Chiara Bucello; James Lemon; Lucas Wiessing; Mathew Hickman Journal: Bull World Health Organ Date: 2013-02-01 Impact factor: 9.408
Authors: Keri N Althoff; Kathleen A McGinnis; Christina M Wyatt; Matthew S Freiberg; Cynthia Gilbert; Krisann K Oursler; David Rimland; Maria C Rodriguez-Barradas; Robert Dubrow; Lesley S Park; Melissa Skanderson; Meredith S Shiels; Stephen J Gange; Kelly A Gebo; Amy C Justice Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Stephanie Parent; Seonaid Nolan; Nadia Fairbairn; Monica Ye; Anthony Wu; Julio Montaner; Rolando Barrios; Lianping Ti Journal: Int J Drug Policy Date: 2019-03-18
Authors: Theresa W Kim; Jeffrey H Samet; Sara Lodi; Simeon D Kimmel; Leah S Forman; Marlene C Lira; Jane M Liebschutz; Emily C Williams; Alexander Y Walley Journal: AIDS Behav Date: 2022-06-23
Authors: Sara E Heins; Christine Buttorff; Courtney Armstrong; Rosalie Liccardo Pacula Journal: Drug Alcohol Depend Date: 2021-09-22 Impact factor: 4.492
Authors: Jake R Morgan; Bruce R Schackman; Zoe M Weinstein; Alexander Y Walley; Benjamin P Linas Journal: Drug Alcohol Depend Date: 2019-05-03 Impact factor: 4.852
Authors: Paul J Joudrey; Maria R Khan; Emily A Wang; Joy D Scheidell; E Jennifer Edelman; D Keith McInnes; Aaron D Fox Journal: Addict Sci Clin Pract Date: 2019-04-15
Authors: Jonathan Colasanti; Marlene C Lira; Debbie M Cheng; Jane M Liebschutz; Judith I Tsui; Leah S Forman; Meg Sullivan; Alexander Y Walley; Carly Bridden; Christin Root; Melissa Podolsky; Catherine Abrams; Kishna Outlaw; Catherine E Harris; Wendy S Armstrong; Jeffrey H Samet; Carlos Del Rio Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Amy C Justice; Kirsha S Gordon; Jonathon Romero; E Jennifer Edelman; Benjamin J Garcia; Piet Jones; Saye Khoo; Vincent Lo Re; Christopher T Rentsch; Janet P Tate; Alice Tseng; Julie Womack; Daniel Jacobson Journal: Lancet Healthy Longev Date: 2021-09-29